Customize At3g22650 Antibody

Description

Overview of At3g22650 Antibody

The At3g22650 Antibody (product code: CSB-PA878595XA01DOA) is a polyclonal antibody targeting the protein encoded by the At3g22650 gene in Arabidopsis thaliana (Mouse-ear cress). This antibody is listed in commercial catalogs as a research tool for studying plant biology, particularly in the context of gene expression and protein function in Arabidopsis. The product is available in two formats: 2 mL and 0.1 mL volumes, with specifications tailored for experimental use in plant molecular biology .

Research Applications and Limitations

While the antibody is marketed for plant research, no peer-reviewed studies or experimental data (e.g., ELISA, Western blot, or immunohistochemistry results) are publicly available in the provided sources to validate its efficacy or specificity. This contrasts with well-characterized antibodies in other contexts, such as:

Monoclonal antibodies in cancer therapy (e.g., anti-CD30/CD3 bispecific antibodies) .
Antibody-based diagnostics for Alzheimer’s disease (e.g., tau-targeting antibodies) .
Structural prediction methods for identifying antibody lineages (e.g., Rosetta-derived scoring matrices) .

For At3g22650 Antibody, researchers would need to consult the supplier (Cusabio) for technical data sheets or conduct internal validation experiments.

Comparative Analysis of Arabidopsis Antibodies

The table below highlights other Arabidopsis antibodies listed in the same catalog, demonstrating the antibody’s position within a broader research toolkit:

Product Code	Target Gene	UniProt ID	Species
CSB-PA879894XA01DOA	At4g29970	Q9SZR7	Arabidopsis thaliana
CSB-PA862957XA01DOA	At4g05620	Q9M0U2	Arabidopsis thaliana
CSB-PA878595XA01DOA	At3g22650	Q9LUJ6	Arabidopsis thaliana
CSB-PA648067XA01DOA	At3g59000	Q2V3N5	Arabidopsis thaliana

Recommendations for Researchers

Validation: Confirm specificity using Western blot or immunofluorescence with Arabidopsis tissues.
Cross-Reactivity: Test against related proteins (e.g., orthologs in other plant species).
Collaboration: Partner with plant biology labs to expand the antibody’s experimental database.

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Components: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

At3g22650 antibody; MWI23.2Putative F-box protein At3g22650 antibody

Target Names

At3g22650

Uniprot No.

Q9LUJ6

Q&A

FAQs for At3g22650 Antibody Research
Note: While no direct studies on At3g22650 were identified in the provided literature, these FAQs are structured using methodological frameworks from analogous antibody research in virology, amyloid biology, and immunology.

Advanced Research Questions

How to resolve discrepancies between in vitro neutralizing activity and in vivo protection?
- Case study:
  - Ab10 showed 90% in vitro neutralization but required high doses for in vivo efficacy .
- Methodological solutions:
  - Conduct pharmacokinetic/pharmacodynamic (PK/PD) modeling to optimize dosing regimens.
  - Evaluate Fc-mediated effector functions (e.g., ADCC, ADCP) using assays like ADCVI .
How to design epitope mapping for conformation-dependent antibodies?
- Approach:
  - Use cross-linker-assisted mass spectrometry to identify non-linear epitopes (e.g., Ab10’s Gn glycoprotein epitope) .
  - Perform alanine scanning mutagenesis to pinpoint critical residues .
How does allotypic variation impact antibody function?
- Key findings:
  
  IgG Subtype Allotype Functional Impact
  IgG3-H H4 variant Superior ADCVI and neutralization vs. IgG1
  IgG3-KVH P5C3 variant Reduced plasma half-life despite enhanced binding
- Recommendation: Prioritize allotype characterization during therapeutic development.
What strategies mitigate cytokine release syndrome in immunomodulatory antibodies?
- Lessons from anti-CD3ε antibodies:
  - Target non-mitogenic epitopes (e.g., 20-2b2 vs. OKT3) .
  - Engineer Fc domains to reduce FcγR binding while retaining immunosuppressive activity .

IgG Subtype	Allotype	Functional Impact
IgG3-H	H4 variant	Superior ADCVI and neutralization vs. IgG1
IgG3-KVH	P5C3 variant	Reduced plasma half-life despite enhanced binding

Data Contradiction Analysis

How to interpret conflicting results between antibody-mediated amyloid clearance and cognitive outcomes?
- Example: 3H3 reduced Aβ plaques but showed limited cognitive improvement .
- Resolution framework:
  1. Assess antibody penetration across the blood-brain barrier (BBB).
  2. Evaluate off-target effects on non-amyloid proteins (e.g., λ light chains) .
  3. Use synaptic plasticity assays (e.g., hippocampal LTP) to quantify functional recovery .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

At3g22650 Antibody